This product is delipidated during its purification process from human plasma. Although it is not routinely tested for final lipid contamination, previous lots have been tested by SPIFE Vis Cholesterol Gel against a cholesterol profile standard and no visible lipid contamination had been found.
A0722
Apolipoprotein A-I from human plasma
≥85% (SDS-PAGE), buffered aqueous solution
Synonym(s):
Apo A-I
Sign In to View Organizational & Contract Pricing.
Select a Size
0.5 MG
CZK 6,370.00
1 MG
CZK 10,900.00
About This Item
Skip To
biological source
human plasma
Quality Level
assay
≥85% (SDS-PAGE)
form
buffered aqueous solution
mol wt
28.3 kDa
technique(s)
ELISA: suitable
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
Gene Information
human ... APOA1(335)
Looking for similar products? Visit Product Comparison Guide
Related Categories
1 of 4
This Item | |||
|---|---|---|---|
| assay ≥85% (SDS-PAGE) | assay ≥95% (SDS-PAGE) | assay ≥95% (SDS-GE) | assay ≥95% (SDS-PAGE) |
| technique(s) ELISA: suitable | technique(s) - | technique(s) electrophoresis: suitable | technique(s) - |
| biological source human plasma | biological source human plasma | biological source human plasma | biological source - |
| form buffered aqueous solution | form buffered aqueous solution | form buffered aqueous solution | form liquid |
| storage temp. −20°C | storage temp. −20°C | storage temp. −20°C | storage temp. −20°C |
| shipped in dry ice | shipped in dry ice | shipped in - | shipped in wet ice |
Application
Apolipoprotein A-I from human plasma has been used to induce cholesterol efflux in nitrobenzoxadiazole (NBD)-cholesterol loaded cells. It has also been used to detect IgG anti-apoA-1 antibodies using enzyme linked immunosorbent assay (ELISA).
Major protein components in high density lipoprotein (HDL)
Biochem/physiol Actions
Activates lecithin-cholesterol acyltransferase (LCAT), which is responsible for cholesterol esterification in plasma.
Apo-AI comprises ~70% of the protein moiety in HDL. It is a single polypeptide chain consisting of 245 amino acids with glutamic acid as the C-terminal residue and aspartic acid as the N-terminal residue. The molecular mass is reported to be 28.3 kDa. The protein is made up of one major isoform (pI 5.6) and two minor isoforms (pI 5.53 and 5.46). Apo-AI shows a high content of α-helix structure. The amphipathic regions in the α-helix structure seem to be responsible for lipid binding capacity. In aqueous solution, Apo-AI shows self-association with minor conformation change. Apo-AI activates lecithin-cholesterol (LCAT) acyltransferase, which is responsible for cholesterol esterification in plasma.
Apo-AI levels in normal plasma are 90-130 mg/dl. Apo-AI levels may be inversely related to the risk of coronary disease.
Apo-AI levels in normal plasma are 90-130 mg/dl. Apo-AI levels may be inversely related to the risk of coronary disease.
Physical form
Solution in 10 mM ammonium bicarbonate
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Storage Class
10 - Combustible liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Gantsetseg Tumurkhuu et al.
Cell metabolism, 28(3), 432-448 (2018-06-26)
Pathogen burden accelerates atherosclerosis, but the mechanisms remain unresolved. Activation of the NLRP3 inflammasome is linked to atherogenesis. Here we investigated whether Chlamydia pneumoniae (C.pn) infection engages NLRP3 in promoting atherosclerosis. C.pn potentiated hyperlipidemia-induced inflammasome activity in cultured macrophages and
Anti-ApoA-I IgG antibodies are not associated with carotid artery disease progression and first-time cardiovascular events in middle-aged individuals
Lagerstedt JO, et al.
Journal of Internal Medicine, 285(1), 49-58 (2019)
J O Lagerstedt et al.
Journal of internal medicine, 285(1), 49-58 (2018-07-22)
IgG antibodies against apolipoprotein A-I (ApoA-I) have been found to be elevated in subjects from the general population with clinically manifest cardiovascular disease and in myocardial infarction patients with an adverse prognosis. Here, we investigated whether these antibodies are prospectively
Sara Croca et al.
Arthritis research & therapy, 17, 26-26 (2015-04-19)
IgG anti-apolipoprotein A-1 (IgG anti-apoA-1) antibodies are present in patients with systemic lupus erythematosus (SLE) and may link inflammatory disease activity and the increased risk of developing atherosclerosis and cardiovascular disease (CVD) in these patients. We carried out a rigorous
H J Menzel et al.
The Journal of biological chemistry, 259(5), 3070-3076 (1984-03-10)
Variant forms of apolipoprotein A-I (apo-A-I) have been shown to exist in the human population. One mutant form, referred to as apo-A-I-Münster-3, is one charge unit more basic than normal apo-A-I on isoelectric focusing gels. This variant has the same
Articles
Lipoproteins package cholesterol for transport in plasma, essential for lipid transport and cellular function in the body.
Related Content
Global Trade Item Number
| SKU | GTIN |
|---|---|
| A0722-.5MG | 04061833334317 |
| A0722-1MG | 04061833334324 |
-
Is Product No. A0722, ApoA1 delipidated?
1 answer-
Helpful?
-
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service